the coarse crackle

TETON-2 was a 52-week, phase 3, double-blind, randomized, placebo-controlled trial evaluating inhaled treprostinil in patients with idiopathic pulmonary fibrosis, most of whom were on background antifibrotic therapy. Treprostinil (target 12 breaths four times daily) reduced median decline in absolute FVC versus placebo (between-group difference 95.6 ml) and reduced time to first clinical worsening (death, respiratory hospitalization, or ≥10% relative FVC decline, with a hazard ratio of 0.71).